24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference
Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325
Phase 2 clinical studies of UBX1325 currently enrolling patients with DME and wAMD
https://finance.yahoo.com/news/unity-biotechnology-announces-additional-data-130000317.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.